Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Lawrence M. Kauvar"'
Publikováno v:
Therapeutic Advances in Infectious Disease, Vol 10 (2023)
Background: Respiratory syncytial virus (RSV) is a poor inducer of antiviral interferon (IFN) responses which result in incomplete immunity and RSV disease. Several RSV proteins alter antiviral responses, including the non-structural proteins (NS1, N
Externí odkaz:
https://doaj.org/article/1ef21606933c49368af252c277503990
Autor:
Zachary D. C. Burke, Christopher M. Hart, Benjamin V. Kelley, Zeinab Mamouei, Gideon W. Blumstein, Christopher Hamad, Kellyn Hori, Nicolas Cevallos, Christina Villalpando, Nicole Truong, Amr Turkmani, Micah Ralston, Aaron Kavanaugh, Edgar Tenorio, Lawrence M. Kauvar, Alan Li, Nathanael Prunet, Alexandra I. Stavrakis, Nicholas M. Bernthal
Publikováno v:
Antibiotics, Vol 12, Iss 10, p 1490 (2023)
Bacterial biofilms on orthopedic implants are resistant to the host immune response and to traditional systemic antibiotics. Novel therapies are needed to improve patient outcomes. TRL1068 is a human monoclonal antibody (mAb) against a biofilm anchor
Externí odkaz:
https://doaj.org/article/64cfd71921e94a6890bf163a384a5fc1
Autor:
Harrison C. Bergeron, Jackelyn Murray, Aakash Arora, Ana M. Nuñez Castrejon, Rebecca M. DuBois, Larry J. Anderson, Lawrence M. Kauvar, Ralph A. Tripp
Publikováno v:
Viruses, Vol 15, Iss 5, p 1067 (2023)
The respiratory syncytial virus (RSV) causes significant respiratory disease in young infants and the elderly. Immune prophylaxis in infants is currently limited to palivizumab, an anti-RSV fusion (F) protein monoclonal antibody (mAb). While anti-F p
Externí odkaz:
https://doaj.org/article/9f95ee6739094f5ab2af96faa0207fd3
Autor:
Ying Qi, Li He, Xiaohong Cui, Laura Hertel, Daniel C. Freed, Tong-Ming Fu, Lawrence M. Kauvar, Michael A. McVoy, Qiang Ruan
Publikováno v:
Virology Journal, Vol 17, Iss 1, Pp 1-7 (2020)
Abstract Antibody neutralization of cytomegalovirus (CMV) entry into diverse cell types is a key consideration for development of vaccines and immunotherapeutics. CMV entry into fibroblasts differs significantly from entry into epithelial or endothel
Externí odkaz:
https://doaj.org/article/8f1024c2a3ed43b395ff4e6e9054c92e
Autor:
Diego R. Hijano, Luan D. Vu, Lawrence M. Kauvar, Ralph A. Tripp, Fernando P. Polack, Stephania A. Cormier
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract disease in children
Externí odkaz:
https://doaj.org/article/17a5a6024e0548289502cc2282c404c8
Autor:
Martin Zydek, Matthew Petitt, June Fang-Hoover, Barbara Adler, Lawrence M. Kauvar, Lenore Pereira, Takako Tabata
Publikováno v:
Viruses, Vol 6, Iss 3, Pp 1346-1364 (2014)
Human cytomegalovirus (HCMV) is the major viral cause of congenital infection and birth defects. Primary maternal infection often results in virus transmission, and symptomatic babies can have permanent neurological deficiencies and deafness. Congeni
Externí odkaz:
https://doaj.org/article/649e05e2827644dba22d79d8f81c69f8
Publikováno v:
International Journal of Molecular Sciences, Vol 19, Iss 12, p 3982 (2018)
Hyperimmune globulin (HIG) has shown efficacy against human cytomegalovirus (HCMV) for both transplant and congenital transmission indications. Replicating that activity with a monoclonal antibody (mAb) offers the potential for improved consistency i
Externí odkaz:
https://doaj.org/article/8a960e074e0545fbbaa181d76b474483
Publikováno v:
PLoS ONE, Vol 14, Iss 7, p e0219256 (2019)
We have previously described a native human monoclonal antibody, TRL1068, that disrupts bacterial biofilms by extracting from the biofilm matrix key scaffolding proteins in the DNABII family, which are present in both gram positive and gram negative
Externí odkaz:
https://doaj.org/article/f3d9543f9995425d8634ecb15aa67f65
Publikováno v:
Journal of virology, vol 96, iss 7
Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract disease of children, the elderly, and immunocompromised individuals. Currently, there are no FDA-approved RSV vaccines. The RSV G glycoprotein is used for viral at
Autor:
Susanna F. Greer, Zehava Eichenbaum, Ya Shu Huang, Nilanjana Chatterjee, Lawrence M. Kauvar, Kristin V. Lyles, Julie E. Morgan
Publikováno v:
J Infect Dis
Background A vaccine against group A Streptococcus (GAS) has been actively pursued for decades. The surface receptor Shr is vital in GAS heme uptake and provides an effective target for active and passive immunization. Here, we isolated human monoclo